Myomo Q3 EPS Forecast Boosted by Ascendiant Capital Markets

Myomo, Inc. (NYSEAMERICAN:MYO) – Ascendiant Capital Markets upped their Q3 2026 earnings per share (EPS) estimates for shares of Myomo in a report issued on Wednesday, August 26th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings of ($0.08) per share for the quarter, up from their prior estimate of ($0.09). Ascendiant Capital Markets currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.33) per share. Ascendiant Capital Markets also issued estimates for Myomo’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.32) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.22) EPS.

Myomo (NYSEAMERICAN:MYO) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $11.70 million for the quarter, compared to the consensus estimate of $10.35 million. Myomo had a negative return on equity of 138.85% and a negative net margin of 33.53%.

Myomo Stock Down 6.9%

Shares of NYSEAMERICAN MYO opened at $1.49 on Tuesday. The company has a quick ratio of 2.01, a current ratio of 2.31 and a debt-to-equity ratio of 1.98. The firm has a market cap of $59.02 million, a PE ratio of -4.38 and a beta of 1.50. The company’s fifty day simple moving average is $1.24 and its 200 day simple moving average is $1.01. Myomo has a 12-month low of $0.60 and a 12-month high of $1.89.

Insider Transactions at Myomo

In other Myomo news, Director Thomas F. Kirk bought 40,002 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was bought at an average cost of $1.27 per share, with a total value of $50,802.54. Following the completion of the transaction, the director directly owned 693,865 shares in the company, valued at approximately $881,208.55. The trade was a 6.12% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Harry Kovelman sold 17,250 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $1.73, for a total transaction of $29,842.50. Following the completion of the sale, the insider owned 105,983 shares in the company, valued at $183,350.59. This represents a 14.00% decrease in their position. The disclosure for this sale is available in the SEC filing. 12.14% of the stock is owned by company insiders.

Institutional Investors Weigh In On Myomo

Institutional investors have recently bought and sold shares of the stock. Engineers Gate Manager LP raised its position in Myomo by 62.8% in the 2nd quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock valued at $65,000 after buying an additional 11,614 shares during the last quarter. Bank of America Corp DE boosted its holdings in Myomo by 93.6% during the 3rd quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock worth $27,000 after acquiring an additional 14,705 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Myomo in the 1st quarter worth $75,000. Invesco Ltd. purchased a new stake in shares of Myomo in the second quarter valued at about $37,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Myomo in the second quarter valued at about $38,000. Institutional investors own 44.99% of the company’s stock.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.